中国制药企业在美国市场中应对授权仿制药竞争的策略研究  

Research on Strategy of China Pharmaceutical Companies Coping with Competition of Authorized Generics in American Drug Market

作　　者：刘立春[1] 朱雪忠[2] 

机构地区：[1]华中科技大学知识产权战略研究院,武汉430074 [2]同济大学知识产权学院,上海200092

出　　处：《中国药学杂志》2013年第14期1217-1222,共6页Chinese Pharmaceutical Journal

基　　金：国家自然科学基金资助项目(71003037);教育部人文社会科学研究一般项目(11YJA630224)

摘　　要：目的通过对美国授权仿制药战略原理、特点以及影响进行研究,为中国学者探讨授权仿制药战略以及中国制药企业在美国市场面临授权仿制药竞争时提供借鉴。方法通过案例分析和政策解析,总结品牌药厂商在美国市场中使用授权仿制药策略的特点。结论与结果成功的授权仿制药战略能够使品牌药厂商的产品在专利到期后仍能后维持较大的市场份额。中国制药企业需要根据自身的情况在美国市场选择不同的授权仿制药策略。ObjectiveTo study the principle, feature and impact of the authorized generics strategy in American drug market, thus to provide some references for Chinese scholars who research the authorized generics strategy and for China pharmaceutical companies that would face competition in American pharmaceutical market. Methods By case study and policies analysis, the ways how the brand-name companies used the authorized generics in American drug market were summarized. Results AND Conclusion Successful authorized generics strategy can maintain a large market share of the brand-name companies products. In American drug market, there are some particularities about the authorize generics strategy due to the features of American drug policies and regulations. China pharmaceutical companies should implement different authorized generics strategy according to their own conditions in American drug market at present.

关 键 词：授权仿制药 独立仿制药 品牌药 专利 战略 

分 类 号：R95[医药卫生—药学]